Contribution of Fetal Magnetocardiography to Diagnosis, Risk Assessment, and Treatment of Fetal Arrhythmia.
Annette Wacker‐Gussmann,Janette F. Strasburger,Ronald T. Wakai
DOI: https://doi.org/10.1161/JAHA.121.025224
IF: 6.106
2022-07-30
Journal of the American Heart Association
Abstract:Background Fetal echocardiography has been the mainstay of fetal arrhythmia diagnosis; however, fetal magnetocardiography (fMCG) has recently become clinically available. We sought to determine to what extent fMCG contributed to the precision and accuracy of fetal arrhythmia diagnosis and risk assessment, and in turn, how this altered pregnancy management. Methods and Results We reviewed fMCG tracings and medical records of 215 pregnancies referred to the Biomagnetism Laboratory, UW‐Madison, over the last 10 years, because of fetal arrhythmia or risk of arrhythmia. We compared referral diagnosis and treatment with fMCG diagnosis using a rating scale and restricted our review to the 144 subjects from the tachycardia, bradycardia/AV block, and familial long QT syndrome categories. Additional fMCG findings beyond those of the referring echocardiogram, or an alternative diagnosis were seen in 117/144 (81%), and 81 (56%) were critical changes. Eight (5.5%) had resolution of arrhythmia before fMCG. At least moderate changes in management were seen in 109/144 (76%) fetuses, of which 35/144 (24%) were major. The most diverse fMCG presentation was long QT syndrome, present in all 3 referral categories. Four of 5 stillbirths were seen with long QT syndrome. Nine fetuses showed torsades de pointes ventricular tachycardia, of which only 2 were recognized before fMCG. Conclusions FMCG has a significant impact on prenatal diagnosis and management of arrhythmias or familial arrhythmia risk, which cannot be fully met by existing technology. The combination of fMCG and fetal echocardiography in fetal care centers will be needed in the future to optimize care. Nonstandard Abbreviations and Acronyms AVB atrioventricular block BAB blocked atrial bigeminy fMCG fetal magnetocardiography LQTS long QT syndrome PVCs premature ventricular contractions SSA/Ro Sjogren's antibody A SVT supraventricular tachycardia TdP torsades de pointes ventricular tachycardia TWA T wave alternans Clinical Perspective What Is New? Fetal magnetocardiography (fMCG) is an advanced technology similar to postnatal electrocardiography or Holter monitoring. In 144 high‐risk pregnant subjects with or at risk for fetal arrhythmias related to tachycardia, atrioventricular block, and long QT syndrome, fMCG supplemented and/or changed the clinical diagnosis in over half of fetuses studied by (1) dispelling ambiguity of echocardiographic rhythm diagnosis, and/or (2) uncovering new unsuspected rhythm or conduction abnormalities. What Are the Clinical Implications? fMCG findings led to major clinical fetal–maternal management changes in one quarter of patients, often resulting in a safer maternal care plan. Seven of 9 cases of torsades de pointes were not detected by echocardiography before fMCG. Correct fetal rhythm diagnosis provided by a combination of fMCG and fetal echocardiography, in the future, may improve maternal–fetal outcomes. Fetal magnetocardiography (fMCG) is a promising technology that safely and noninvasively records the natural electromagnetic signal of the fetal heart. 1 , 2 , 3 New optically pumped magnetometer sensors, and person‐sized magnetic shields have lowered technology cost and will likely soon facilitate broader adoption. 4 , 5 Like postnatal ECG, fMCG allows precise assessment of cardiac time intervals (RR, P, PR, QRS, QT, U, and QTc), signal characteristics, and diverse rhythm patterns. The Scientific Statement of the American Heart Association supports the use of fMCG to assess cardiac conduction and rhythm in fetuses with known or suspected conduction system abnormalities, a Category 2a recommendation (ie, benefits>>risks) and stated that no other techni -Abstract Truncated-
cardiac & cardiovascular systems